Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT06500702 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06500702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06500702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
December 19, 2024
Completion date
February 16, 2028
Enrollment
84 (estimated)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis, glomerulonephritis minimal lesion